Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2024-10-03 00:00:00 ET · period of report 2024-10-02 · accession 0001787306-24-000136 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-10-03 | 2024-10-02 | ARQT | Edwards Larry Todd | SVP Chief Commercial Off | S - Sale | $10.01 | -3,725 | 136.6K | -3% | -$37.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-10-02 | S | D | 3,725 | $10.01 | 136,635 | D | — | — | (F2) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $9.51 to $10.31, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |